"Amundi SA Chief Executive Officer Yves Perrier is stepping down after more than a decade atop the firm he helped build into the largest asset manager in Europe." POINT OF NOTE: Amundi, Europe’s largest asset management company, and Bank of China Wealth Management said they had won approval from Chinese regulators to set up a joint venture in the country. (Reuters).
https://www.msn.com/en-us/money/companies/amundi-ceo-steps-down-after-building-europe-s-top-fund-firm/ar-BB1dytTe?appwebview=true
"BEIJING, China, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), a leading high-performance computing solutions provider, today announced that Mr. Quanfu Hong has resigned from the Chief Financial Officer position, effective February 9, 2021, for personal reasons. Mr. Tong He will become acting Chief Financial Officer immediately." " Canaan Inc. is currently focused on the research and development of advanced technology, including such areas as AI chips, AI algorithms, AI architectures, system on a chip (SoC) integration and chip integration." https://apnews.com/press-release/globenewswire-mobile/technology-business-executive-changes-greater-china-financial-technology-401f8b51e543ef2a5035671d188c3b3f
"February 09, 2021 (ACCESSWIRE via COMTEX) -- GENEVA, SWITZERLAND / ACCESSWIRE / February 9, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) ("Relief" or the "Company") announces the resignation, effective immediately, of Board of Directors member Thomaz Burckhardt. Mr. Burckhardt has resigned to focus his time and efforts on other professional duties and interests." "Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM." https://www.marketwatch.com/press-release/relief-announces-resignation-of-thomaz-burckhardt-as-member-of-the-board-of-directors-2021-02-09
"BEIJING, Feb. 08, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (NASDAQ: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that Mr. Chenglong Zhu has tendered his resignation as a director of the Company for personal reasons, effective on February 4, 2021. Mr. Chenglong Zhu’s resignation did not result from any disagreement with the Company." https://apnews.com/press-release/globenewswire-mobile/technology-business-executive-changes-financial-technology-corporate-news-3f316033d0a09d9efe310357729ec8a4
"BEIJING, China, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), a leading high-performance computing solutions provider, today announced that Mr. Quanfu Hong has resigned from the Chief Financial Officer position, effective February 9, 2021, for personal reasons. Mr. Tong He will become acting Chief Financial Officer immediately."
" Canaan Inc. is currently focused on the research and development of advanced technology, including such areas as AI chips, AI algorithms, AI architectures, system on a chip (SoC) integration and chip integration."
https://apnews.com/press-release/globenewswire-mobile/technology-business-executive-changes-greater-china-financial-technology-401f8b51e543ef2a5035671d188c3b3f
"February 09, 2021 (ACCESSWIRE via COMTEX) -- GENEVA, SWITZERLAND / ACCESSWIRE / February 9, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) ("Relief" or the "Company") announces the resignation, effective immediately, of Board of Directors member Thomaz Burckhardt. Mr. Burckhardt has resigned to focus his time and efforts on other professional duties and interests."
"Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM."
"BEIJING, Feb. 08, 2021 (GLOBE NEWSWIRE) -- UP Fintech Holding Limited (NASDAQ: TIGR) (“UP Fintech” or the “Company”), a leading online brokerage firm focusing on global investors, today announced that Mr. Chenglong Zhu has tendered his resignation as a director of the Company for personal reasons, effective on February 4, 2021. Mr. Chenglong Zhu’s resignation did not result from any disagreement with the Company."